{
  "citations" : [ {
    "@id" : "https://pharmgkb.org/literature/15105062",
    "@context" : "https://api.pharmgkb.org/jsonld/literature.jsonld",
    "id" : 15105062,
    "title" : "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.",
    "_sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/32189324",
    "authors" : [ "Theken Katherine N", "Lee Craig R", "Gong Li", "Caudle Kelly E", "Formea Christine M", "Gaedigk Andrea", "Klein Teri E", "Agúndez José A G", "Grosser Tilo" ],
    "crossReferences" : [ {
      "@id" : "https://pharmgkb.org/crossReference/pubMed/32189324",
      "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
      "id" : 1451090662,
      "resource" : "PubMed",
      "resourceId" : "32189324",
      "_url" : "https://www.ncbi.nlm.nih.gov/pubmed/32189324",
      "version" : 0
    }, {
      "@id" : "https://pharmgkb.org/crossReference/doi/10.1002/cpt.1830",
      "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
      "id" : 1451090663,
      "resource" : "DOI",
      "resourceId" : "10.1002/cpt.1830",
      "_url" : "http://dx.doi.org/10.1002%2Fcpt.1830",
      "version" : 0
    } ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ ],
    "meshTerms" : [ ],
    "month" : 3,
    "nonHuman" : false,
    "objCls" : "Literature",
    "pediatric" : false,
    "pgkbPublication" : true,
    "pubDate" : "2020-03-01T00:00:00-08:00",
    "summary" : "Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used analgesics due to their lack of addictive potential. However, NSAIDs have the potential to cause serious gastrointestinal, renal, and cardiovascular adverse events. CYP2C9 polymorphisms influence metabolism and clearance of several drugs in this class, thereby affecting drug exposure and potentially safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for NSAIDs based on CYP2C9 genotype (updates at www.cpicpgx.org).",
    "version" : 1,
    "year" : 2020
  } ],
  "guideline" : {
    "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166222201",
    "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
    "objCls" : "Guideline Annotation",
    "id" : "PA166222201",
    "name" : "Annotation of CPIC Guideline for aceclofenac, aspirin, diclofenac, dipyrone, indomethacin, lumiracoxib, nabumetone, naproxen and CYP2C9",
    "cancerGenome" : false,
    "crossReferences" : [ {
      "@id" : "https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/",
      "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
      "id" : 1451251583,
      "resource" : "URL",
      "resourceId" : "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/",
      "_url" : "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/",
      "version" : 0
    } ],
    "descriptiveVideoId" : "bO6Kk6hx78Q",
    "guidelineGenes" : [ ],
    "history" : [ {
      "id" : 1451251622,
      "date" : "2020-08-19T00:00:00-07:00",
      "type" : "Create",
      "version" : 0
    }, {
      "id" : 1451613160,
      "date" : "2021-12-10T11:11:00.330-08:00",
      "description" : "Added video",
      "type" : "Update",
      "version" : 0
    } ],
    "literature" : [ {"@id":"https://pharmgkb.org/literature/15105062","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15105062,"title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.","_sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/32189324","crossReferences":[{"@id":"https://pharmgkb.org/crossReference/pubMed/32189324","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1451090662,"resource":"PubMed","resourceId":"32189324","_url":"https://www.ncbi.nlm.nih.gov/pubmed/32189324"},{"@id":"https://pharmgkb.org/crossReference/doi/10.1002/cpt.1830","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1451090663,"resource":"DOI","resourceId":"10.1002/cpt.1830","_url":"http://dx.doi.org/10.1002%2Fcpt.1830"}],"objCls":"Literature"} ],
    "pediatric" : false,
    "recommendation" : false,
    "relatedAlleles" : [ ],
    "relatedChemicals" : [ {
      "@id" : "https://pharmgkb.org/chemical/PA166049185",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA166049185",
      "name" : "aceclofenac",
      "version" : 6
    }, {
      "@id" : "https://pharmgkb.org/chemical/PA448497",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA448497",
      "name" : "aspirin",
      "version" : 15
    }, {
      "@id" : "https://pharmgkb.org/chemical/PA449293",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA449293",
      "name" : "diclofenac",
      "version" : 9
    }, {
      "@id" : "https://pharmgkb.org/chemical/PA166128206",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA166128206",
      "name" : "dipyrone",
      "version" : 4
    }, {
      "@id" : "https://pharmgkb.org/chemical/PA449982",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA449982",
      "name" : "indomethacin",
      "version" : 9
    }, {
      "@id" : "https://pharmgkb.org/chemical/PA164769031",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA164769031",
      "name" : "lumiracoxib",
      "version" : 4
    }, {
      "@id" : "https://pharmgkb.org/chemical/PA450572",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA450572",
      "name" : "nabumetone",
      "version" : 9
    }, {
      "@id" : "https://pharmgkb.org/chemical/PA450595",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA450595",
      "name" : "naproxen",
      "version" : 11
    } ],
    "relatedGenes" : [ {
      "@id" : "https://pharmgkb.org/gene/PA126",
      "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
      "objCls" : "Gene",
      "id" : "PA126",
      "symbol" : "CYP2C9",
      "name" : "cytochrome P450 family 2 subfamily C member 9",
      "version" : 7876
    } ],
    "source" : "CPIC",
    "summaryMarkdown" : {
      "id" : 1451251620,
      "html" : "<p>There are currently no recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes.</p>\n",
      "version" : 0
    },
    "terms" : [ ],
    "textMarkdown" : {
      "id" : 1451433685,
      "html" : "<p>This annotation is based on the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/\" target=\"_blank\">CPIC&reg; guideline for Nonsteroidal Anti-inflammatory Drugs and CYP2C9</a>. The CPIC authors have evaluated therapeutic dose recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes. They conclude that there is insufficient evidence to provide a recommendation to guide clinical practice at this time.</p>\n<h3 id=\"march-2020\">March 2020</h3>\n<ul>\n<li>\n<p>The <a rel=\"noopener noreferrer\" href=\"https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1830\" target=\"_blank\">CPIC guideline regarding for <em>CYP2C9</em> and Nonsteroidal Anti-inflammatory Drugs</a> is published in Clinical Pharmacology and Therapeutics.</p>\n</li>\n<li>\n<p>These guidelines are applicable to:</p>\n<ul>\n<li>\n<p>pediatric patients</p>\n</li>\n<li>\n<p>adult patients</p>\n</li>\n</ul>\n</li>\n<li>\n<p>Excerpts from the 2020 Nonsteroidal Anti-inflammatory Drugs dosing guideline:</p>\n<ul>\n<li>&quot;Aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen. Table S9 includes evidence linking CYP2C9 genotype to aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen phenotype. The pharmacokinetics of these drugs are not significantly impacted by CYP2C9 genetic variants in vivo and/or there is insufficient evidence to provide a recommendation to guide clinical practice at this time (CPIC classification of recommendation “no recommendation”; CPIC level C; Table S20).&quot;</li>\n</ul>\n</li>\n<li>\n<p>Download and read:</p>\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/NSAID/2020/32189324.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for <em>CYP2C9</em> and NSAIDs Therapy</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/NSAID/2020/32189324-supplement.pdf\" target=\"_blank\">2020 supplement</a></li>\n</ul>\n</li>\n</ul>\n",
      "version" : 0
    },
    "userId" : "lgong",
    "version" : 2
  }
}